title: Infralimbic cortex activation increases c-Fos expression in intercalated neurons of the amygdala.
abstract: Recently, it was reported that stimulation of the infralimbic cortex produces a feedforward inhibition of central amygdala neurons. The interest of this observation comes from the fact that the central nucleus is the main output station of the amygdala for conditioned fear responses and evidence that the infralimbic cortex plays a critical role in the extinction of conditioned fear. However, the identity of the neurons mediating this infralimbic-evoked inhibition of the central nucleus remains unknown. Likely candidates are intercalated amygdala neurons. Indeed, these cells receive glutamatergic afferents from the infralimbic cortex, use GABA as a transmitter, and project to the central amygdala. Thus, the present study was undertaken to test whether, in adult rats, the infralimbic cortex can affect the activity of intercalated neurons. To this end, disinhibition of the infralimbic cortex was induced by local infusion of the non-competitive GABA-A receptor antagonist picrotoxin. Subsequently, neuronal activation was determined bilaterally within the amygdala using induction of the immediate early gene Fos. Infralimbic disinhibition produced a significant increase in the number of Fos-immunoreactive intercalated cells bilaterally whereas no change was detected in the central nucleus. In the basolateral amygdaloid complex, increases in the number of Fos-immunoreactive cells only reached significance in the contralateral lateral nucleus. These results suggest that glutamatergic inputs from the infralimbic cortex directly activate intercalated neurons. Thus, our findings raise the possibility that the infralimbic cortex inhibits conditioned fear via the excitation of intercalated cells and the consequent inhibition of central amygdala neurons.
authors.affiliation: Translational Neuroscience Laboratory, McLean Hospital, Belmont, MA 02478, USA. s.berretta@mclean.harvard.edu
authors.forename: S
authors.initials: S
authors.lastname: Berretta
authors.forename: H
authors.initials: H
authors.lastname: Pantazopoulos
authors.forename: M
authors.initials: M
authors.lastname: Caldera
authors.forename: P
authors.initials: P
authors.lastname: Pantazopoulos
authors.forename: D
authors.initials: D
authors.lastname: Paré
mesh_terms: D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D003214:Conditioning, Classical; D005239:Fear / Q000502:physiology; D018756:GABA Antagonists / Q000008:administration & dosage; D007276:Injections, Intraventricular; D007395:Interneurons / Q000187:drug effects / Q000378:metabolism*; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism*; D010852:Picrotoxin / Q000008:administration & dosage; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018756:GABA Antagonists; D010852:Picrotoxin; D016760:Proto-Oncogene Proteins c-fos